Article List

WPRIM Management System> DCMS> Clinical and Molecular Hepatology> 2021> 27> 3

Volume: 27 Issue: 3

1. Risk of hepatocellular carcinoma in untreated patients with chronic hepatitis B: Independent of HBeAg status?	Page:448—450
2. Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma	Page:402—412
3. KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease	Page:363—401
4. Hepatocellular carcinoma statistics in South Korea	Page:512—514
5. An analysis of polygenic risk scores for non-alcoholic fatty liver disease	Page:446—447
6. The major diagnostic role of autoantibodies in the diagnosis of autoimmune hepatitis, a disease of all ages	Page:510—511
7. Serum fibrosis index-based risk score predicts hepatocellular carcinoma in untreated patients with chronic hepatitis B	Page:499—509
8. Loss-of-function HSD17B13 variants, non-alcoholic steatohepatitis and adverse liver outcomes: Results from a multi-ethnic Asian cohort	Page:486—498
9. The impact of unrestricted access to direct-acting antiviral among incarcerated hepatitis C virus-infected patients	Page:474—485
10. Serum milk fat globule-EGF factor 8 protein as a potential biomarker for metabolic syndrome	Page:463—473
11. Outcomes after liver transplantation in Korea: Incidence and risk factors from Korean transplantation registry	Page:451—462
12. Changes in the epidemiology and management of bacterial infections in cirrhosis	Page:437—445
13. β-blockers in advanced cirrhosis: More friend than enemy	Page:425—436
14. Anti-fibrotic treatments for chronic liver diseases: The present and the future	Page:413—424
15. Risk of hepatocellular carcinoma in untreated patients with chronic hepatitis B: Independent of HBeAg status?	Page:448—450
16. Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma	Page:402—412
17. KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease	Page:363—401
18. Hepatocellular carcinoma statistics in South Korea	Page:512—514
19. An analysis of polygenic risk scores for non-alcoholic fatty liver disease	Page:446—447
20. The major diagnostic role of autoantibodies in the diagnosis of autoimmune hepatitis, a disease of all ages	Page:510—511
21. Serum fibrosis index-based risk score predicts hepatocellular carcinoma in untreated patients with chronic hepatitis B	Page:499—509
22. Loss-of-function HSD17B13 variants, non-alcoholic steatohepatitis and adverse liver outcomes: Results from a multi-ethnic Asian cohort	Page:486—498
23. The impact of unrestricted access to direct-acting antiviral among incarcerated hepatitis C virus-infected patients	Page:474—485
24. Serum milk fat globule-EGF factor 8 protein as a potential biomarker for metabolic syndrome	Page:463—473
25. Outcomes after liver transplantation in Korea: Incidence and risk factors from Korean transplantation registry	Page:451—462
26. Changes in the epidemiology and management of bacterial infections in cirrhosis	Page:437—445
27. β-blockers in advanced cirrhosis: More friend than enemy	Page:425—436
28. Anti-fibrotic treatments for chronic liver diseases: The present and the future	Page:413—424